Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORT NASDAQ:AVR NASDAQ:INMD NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$20.04-2.7%$28.92$19.16▼$48.25$999.99M1.26709,377 shs639,230 shsAVRAnteris Technologies Global$9.15-1.7%$7.23$2.85▼$10.14$906.26M1.781.34 million shs691,708 shsINMDInMode$13.45-0.3%$13.92$12.72▼$16.74$854.71M1.94812,057 shs448,432 shsSGHTSight Sciences$5.13+7.1%$4.45$3.11▼$9.24$260.62M2.41141,280 shs155,417 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+0.54%-1.00%-11.11%-43.39%-29.01%AVRAnteris Technologies Global-2.00%-3.52%+38.96%+50.40%+81.84%INMDInMode+0.15%-0.95%-2.46%-0.37%-5.53%SGHTSight Sciences-0.62%+4.13%-2.84%+30.52%+14.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$20.04-2.7%$28.92$19.16▼$48.25$999.99M1.26709,377 shs639,230 shsAVRAnteris Technologies Global$9.15-1.7%$7.23$2.85▼$10.14$906.26M1.781.34 million shs691,708 shsINMDInMode$13.45-0.3%$13.92$12.72▼$16.74$854.71M1.94812,057 shs448,432 shsSGHTSight Sciences$5.13+7.1%$4.45$3.11▼$9.24$260.62M2.41141,280 shs155,417 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+0.54%-1.00%-11.11%-43.39%-29.01%AVRAnteris Technologies Global-2.00%-3.52%+38.96%+50.40%+81.84%INMDInMode+0.15%-0.95%-2.46%-0.37%-5.53%SGHTSight Sciences-0.62%+4.13%-2.84%+30.52%+14.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 2.75Moderate Buy$46.17130.38% UpsideAVRAnteris Technologies Global 2.60Moderate Buy$16.0074.86% UpsideINMDInMode 2.00Hold$16.0018.96% UpsideSGHTSight Sciences 2.44Hold$8.1458.75% UpsideCurrent Analyst Ratings BreakdownLatest SGHT, AORT, AVR, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026AORTArtivion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/1/2026AORTArtivion Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$45.005/29/2026AVRAnteris Technologies Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/28/2026SGHTSight Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$4.35 ➝ $5.155/20/2026AORTArtivion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)5/15/2026AVRAnteris Technologies Global BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$17.00 ➝ $18.005/11/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026AORTArtivion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$53.00 ➝ $48.005/8/2026AORTArtivion Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $44.005/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.005/7/2026INMDInMode Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $14.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$441.33M2.20$1.07 per share18.70$9.46 per share2.12AVRAnteris Technologies Global$1.91M466.31N/AN/A($0.01) per share-915.00INMDInMode$370.49M2.30$1.49 per share9.04$10.78 per share1.25SGHTSight Sciences$77.36M3.61N/AN/A$1.21 per share4.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion$9.77M$0.2483.5026.72N/A2.55%7.15%3.63%8/6/2026 (Estimated)AVRAnteris Technologies Global-$94.14M-$2.23N/AN/AN/A-5,148.78%-124.76%-101.21%8/10/2026 (Estimated)INMDInMode$93.83M$1.369.89N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)SGHTSight Sciences-$38.43M-$0.71N/AN/AN/A-46.83%-52.34%-28.49%8/6/2026 (Estimated)Latest SGHT, AORT, AVR, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026AVRAnteris Technologies Global-$0.2708-$0.28-$0.0092-$0.28$0.77 million$0.49 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 million5/6/2026Q1 2026SGHTSight Sciences-$0.19-$0.24-$0.05-$0.24$18.47 million$19.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/AAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion0.483.862.80AVRAnteris Technologies GlobalN/A20.9320.93INMDInModeN/A8.807.88SGHTSight Sciences0.685.865.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%AVRAnteris Technologies GlobalN/AINMDInMode68.04%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipAORTArtivion6.30%AVRAnteris Technologies Global4.50%INMDInMode6.92%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,80048.54 million45.49 millionOptionableAVRAnteris Technologies Global13897.34 million92.96 millionN/AINMDInMode48063.36 million58.98 millionOptionableSGHTSight Sciences21054.41 million37.60 millionOptionableSGHT, AORT, AVR, and INMD HeadlinesRecent News About These CompaniesSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2026 | marketbeat.comSight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 13, 2026 | seekingalpha.comSight Sciences Earnings Call Signals Disciplined GrowthMay 7, 2026 | tipranks.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comSight Sciences, Inc. (SGHT) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSight Sciences (SGHT) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesMay 6, 2026 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue EstimatesMay 6, 2026 | zacks.comSight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue GuidanceMay 6, 2026 | globenewswire.comSight Sciences to Present at Two Upcoming Investor ConferencesApril 29, 2026 | globenewswire.comSight Sciences Announces the Release of its Sustainability ReportApril 22, 2026 | markets.businessinsider.comSight Sciences Announces the Release of its Sustainability ReportApril 22, 2026 | globenewswire.comSight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026April 21, 2026 | globenewswire.comInsider Selling: Sight Sciences (NASDAQ:SGHT) CFO Sells 7,231 Shares of StockApril 10, 2026 | insidertrades.comInsider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells 2,869 Shares of StockApril 4, 2026 | insidertrades.comSight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and ...April 1, 2026 | finance.yahoo.comSight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingApril 1, 2026 | globenewswire.comSight Sciences secures $34M patent infringement win against AlconMarch 30, 2026 | massdevice.comSight Sciences wins $34M patent ruling against AlconMarch 30, 2026 | msn.comSight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13thMarch 30, 2026 | globenewswire.comSight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® MicrostentMarch 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGHT, AORT, AVR, and INMD Company DescriptionsArtivion NYSE:AORT$20.04 -0.56 (-2.72%) Closing price 03:59 PM EasternExtended Trading$20.11 +0.07 (+0.35%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Anteris Technologies Global NASDAQ:AVR$9.15 -0.16 (-1.72%) Closing price 04:00 PM EasternExtended Trading$9.54 +0.39 (+4.26%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.InMode NASDAQ:INMD$13.45 -0.04 (-0.30%) Closing price 04:00 PM EasternExtended Trading$13.42 -0.04 (-0.26%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.Sight Sciences NASDAQ:SGHT$5.13 +0.34 (+7.10%) Closing price 04:00 PM EasternExtended Trading$5.18 +0.05 (+1.07%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
